The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
This study is ongoing, but not recruiting participants.
AbbVie (prior sponsor, Abbott)
First Posted: January 10, 2012
Last Update Posted: July 17, 2017
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )